exa-cel
Vertex pharmaceuticals,CRISPR therapeutics AG
[]
$vrtx $crsp vertex and crispr therapeutics present new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel) at the 2022 european hematology association (eha) congress
The information in these Market Commentaries do not constitute a solicitation of the purchase or sale of any stocks ,  or options contracts.